FUNDAMENTALS · Fundamentals · US Healthcare

Align Technology (ALGN) Fundamentals 2026 — P/E 29.3x, Revenue Analysis | SniperIQ

Align Technology (ALGN) is a US-listed Healthcare company in Medical - Devices with a market capitalization of

2.5B, trading at
74.79 on the NASDAQ. This SniperIQ fundamentals page covers Align Technology's valuation (P/E 29.3x, P/B 3.0x), profitability (net margin 10.5%), revenue ($4.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
2.5B
P/E (TTM)29.3x
Net Margin10.5%
Revenue (FY25)$4.0B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Align Technology's market cap?

Align Technology (ALGN) has a market capitalization of approximately

2.5B, trading at
74.79 on the NASDAQ. Market cap moves with the live share price.

What is Align Technology's P/E ratio?

Align Technology's trailing twelve-month P/E ratio is 29.3x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Align Technology?

Align Technology runs a net profit margin of 10.5%, a gross margin of 67.7%, and an operating margin of 14.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Align Technology generate?

Align Technology reported revenue of $4.0B for fiscal year 2025, with net income of $410M and earnings per share (EPS) of 5.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Align Technology pay a dividend?

Align Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Align Technology financially healthy?

Align Technology carries a debt-to-equity ratio of 0.03x and a current ratio of 1.39x, with a market beta of 1.67. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Align Technology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Align Technology (ALGN) the key facts are: market cap

2.5B, P/E 29.3x, revenue $4.0B, 52-week range 122-208.31. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Align Technology's full fundamentals live

Get Align Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Jinyu Bio-technology (600201) fundamentals · Madrigal Pharmaceuticals (MDGL) fundamentals · Guangzhou Kingmed Diagnostics Group (603882) fundamentals · Penumbra (PEN) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons